These findings support the notion that the selective, cell-specific inhibition of DYRK1A could be a promising therapy for AD; however, substantial pharmacological barriers persist in the process for identifying DYRK1A inhibitors, including biochemical properties like limited solubility, subpar blood-brain barrier (BBB) permeability, poor specificity and selectivity, and compliance with long-term safety (Bei et al., 2022; Jarhad et al., 2018; Meine et al., 2018; Powell et al., 2022). The gene discussed is DYRK1A; the disease is Alzheimer disease.